Literature DB >> 11312390

Treatment of recalcitrant orogenital ulceration of Behçet's syndrome with infliximab.

L P Robertson, P Hickling.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11312390     DOI： 10.1093/rheumatology/40.4.473

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN： 1462-0324            Impact factor:   7.580


× No keyword cloud information.
  13 in total

1.  Behçet's syndrome.

Authors:  M R Stanford
Journal:  Br J Ophthalmol       Date:  2003-04       Impact factor: 4.638

Review 2.  Is Optimal Management of Recurrent Aphthous Stomatitis Possible? A Reality Check.

Authors:  Shesha Prasad Ranganath; Anuradha Pai
Journal:  J Clin Diagn Res       Date:  2016-10-01

Review 3.  Behçet's disease: a new target for anti-tumour necrosis factor treatment.

Authors:  P P Sfikakis
Journal:  Ann Rheum Dis       Date:  2002-11       Impact factor: 19.103

Review 4.  Mucocutaneous lesions of Behcet's disease.

Authors:  Erkan Alpsoy; Christos Constantin Zouboulis; George Edward Ehrlich
Journal:  Yonsei Med J       Date:  2007-08-31       Impact factor: 2.759

5.  Successful treatment by azacitidine therapy of intestinal Behçet's disease associated with myelodysplastic syndrome.

Authors:  Hiroaki Tanaka; Naomi Shimizu; Emi Tougasaki; Chika Kawajiri; Shinichiro Hashimoto; Yusuke Takeda; Shio Sakai; Masahiro Takeuchi; Chikako Ohwada; Emiko Sakaida; Toshiyuki Takagi; Chiaki Nakaseko
Journal:  Int J Hematol       Date:  2013-03-22       Impact factor: 2.490

6.  Remission of Behcet's disease with anti-tumor necrosis factor monoclonal antibody therapy: a case report.

Authors:  Salvatore Gulli; Carlo Arrigo; Loredana Bocchino; Lucia Morgante; Donatella Sangari; Irene Castagna; Gian Filippo Bagnato
Journal:  BMC Musculoskelet Disord       Date:  2003-08-28       Impact factor: 2.362

Review 7.  Behçet's disease.

Authors:  Shunsei Hirohata; Hirotoshi Kikuchi
Journal:  Arthritis Res Ther       Date:  2003-04-02       Impact factor: 5.156

Review 8.  Perspectives for TNF-alpha-targeting therapies.

Authors:  Hanns-Martin Lorenz; Joachim R Kalden
Journal:  Arthritis Res       Date:  2002-05-09

9.  Remission of intestinal Behçet's disease treated with anti-tumor necrosis factor alpha monoclonal antibody (Infliximab).

Authors:  Jung Hoon Lee; Tae Nyeun Kim; Sun Taek Choi; Byung Ik Jang; Kyeong-Cheol Shin; Sam Beom Lee; Young Ran Shim
Journal:  Korean J Intern Med       Date:  2007-03       Impact factor: 3.165

10.  Polymorphisms in the tumor necrosis factor gene and susceptibility to Behcet's disease: an updated meta-analysis.

Authors:  Min Zhang; Wang-Dong Xu; Peng-Fei Wen; Yan Liang; Jie Liu; Hai-Feng Pan; Dong-Qing Ye
Journal:  Mol Vis       Date:  2013-09-12       Impact factor: 2.367
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.